The FDA enforcement report dated 21 October lists a Class II recall of compounded tirzepatide/niacinamide injection (2 mL vials, 20 mg/2 mg per mL) from one US compounding pharmacy, Houston Rx, for lack of assurance of sterility. The recall is ongoing.
Class II means use may cause temporary or medically reversible harm, or that serious harm is unlikely. It concerns specific compounded products, not licensed tirzepatide. It follows similar recalls this month of compounded tirzepatide and semaglutide combined with vitamin B12.
The pharmacological point is that additive 'blends' — niacinamide, B12 — have no licensed formulation or dosing evidence, and multi-dose vials of compounded injectables carry their own sterility risk. CDSCO has made no related statement; the products are US-dispensed.
- Ask patients on incretin therapy for the exact product, including any added vitamin, and where it was obtained.
- Multi-dose vials of compounded injectables carry contamination risk with every puncture.
- Added niacinamide or B12 in incretin products is not supported by dosing or efficacy data.
- Report suspected reactions to non-licensed products through national pharmacovigilance.
Why it matters
A run of sterility recalls points to compounded incretins as a recurring safety problem, not a one-off.
Don't overread it
A sterility recall of one pharmacy's product says nothing about licensed tirzepatide.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free